aTYR PHARMA (ATYR) Non-Current Assets (2014 - 2026)

aTYR PHARMA (ATYR) has reported Non-Current Assets for 13 consecutive years, with $11.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 18.37% year-over-year to $11.5 million; the trailing twelve-month figure through Jun 2026 stood at $49.9 million (down 14.17% YoY), and the FY2025 full-year result was $12.8 million, down 14.18% from the prior year.
• Non-Current Assets retreated to $11.5 million in Q2 2026 per ATYR's latest filing, from $12.1 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $18.3 million in Q2 2023 and bottomed at $1.7 million in Q1 2022.
• Historically, Non-Current Assets has averaged $13.4 million across 5 years, with a median of $14.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Non-Current Assets slumped 44.59% in 2022, then jumped 948.28% in 2023.
• Over 5 years, Non-Current Assets stood at $14.9 million in 2022, then rose by 18.41% to $17.7 million in 2023, then declined by 15.77% to $14.9 million in 2024, then fell by 14.18% to $12.8 million in 2025, then dropped by 10.21% to $11.5 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $11.5 million, $12.1 million, and $12.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.